
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc's novel investigational candidate, pemvidutide, has demonstrated significant efficacy in reducing liver fat and improving key biomarkers, as evidenced by a MASLD trial showing up to 76% liver fat reduction and notable ALT improvements. The dual mechanism of action of pemvidutide, leveraging both GLP-1-driven weight loss and glucagon's impact on liver function, positions it favorably for treating both metabolic diseases and ALD, especially with a more favorable tolerability profile compared to existing incretin-based therapies. Additionally, the FDA's openness to non-invasive endpoints for regulatory approval could accelerate pemvidutide's path to market, enhancing its potential for widespread adoption and long-term success.
Bears say
The financial outlook for Altimmune Inc appears negative due to a significant net loss of $23.2 million in the fourth quarter of 2024 and ongoing concerns surrounding clinical development and competitive pressures within the biopharmaceutical sector. The market reception for approved obesity therapies, which includes pemvidutide, remains lukewarm, partly attributed to challenges such as low efficacy and compliance issues, despite the innovative attributes of pemvidutide itself. Additionally, the company faces multiple risks that could hinder its progress, including uncertainties related to reimbursement, commercialization, and external factors impacting clinical trial timelines.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares